Similar articles

• [Are there any advantages of a fixed combination in the treatment of asthma with respect to safety and tolerability?].

  Virchow C. Virchow C. Dtsch Med Wochenschr. 2009 Dec;134 Suppl 10:S376-80. doi: 10.1055/s-0029-1243045. Epub 2009 Nov 25. Dtsch Med Wochenschr. 2009. PMID: 19941240 Review. German. No abstract available.
• Inhaled corticosteroid therapy in asthma: a balancing act.

  Li JT. Li JT. Ann Allergy Asthma Immunol. 1999 Mar;82(3):229-30. doi: 10.1016/S1081-1206(10)62602-6. Ann Allergy Asthma Immunol. 1999. PMID: 10094213 No abstract available.
• Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma.

  Kuna P, Creemers JP, Vondra V, Black PN, Lindqvist A, Nihlen U, Vogelmeier C. Kuna P, et al. Respir Med. 2006 Dec;100(12):2151-9. doi: 10.1016/j.rmed.2006.03.016. Epub 2006 May 15. Respir Med. 2006. PMID: 16701989 Clinical Trial.
• Call for withdrawal of LABA single-therapy inhaler in asthma.

  Beasley R, Perrin K, Weatherall M, Wijesinghe M. Beasley R, et al. Lancet. 2010 Sep 4;376(9743):750-1. doi: 10.1016/S0140-6736(10)61158-0. Lancet. 2010. PMID: 20816529 No abstract available.
• [Do fixed ICS/LABA-combinations have advantages in terms of patient-centered parameters?].

  Buhl R. Buhl R. Dtsch Med Wochenschr. 2009 Dec;134 Suppl 10:S381-5. doi: 10.1055/s-0029-1243046. Epub 2009 Nov 25. Dtsch Med Wochenschr. 2009. PMID: 19941241 Review. German. No abstract available.